Dr. Meletios A Dimopoulos presented an abstract which compared the use of Ixaomib to a placebo for maintenance after a stem cell transplant. This clinical trial was called Tourmaline-MM3, and was chosen as a top 5 abstract by 2 of the 4 doctors who had provided their “Best of the Best” abstracts.
This is the first randomized trial which effectively shows a 39% improvement in progression free survival of an proteasome inhibitor over no maintenance. This now becomes another possible available maintenance strategy. When compared to a previous trial of lenalidomide vs. placebo after stem cell transplant the improvement with lenalidomide was over 100%, however the survival rate after a median follow up of 86 months was only 18%. The Ixazomib trial has not a median follow up of just about two years and no data on the difference in Overall Survival was reported. This should happen in the future, and will be the true measure of Ixazomib as a single agent for maintenance.
Dr. Dimopoulos noted he felt the comparison is somewhat moot because the future of treatments is trending towards combinations and maintenance with ixazomib would be used in this context.
For more information, watch the video of Dr. Francesca Gay describing the results of this study.
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical trials. Founder of Myeloma Crowd, Myeloma Crowd Radio and the CrowdCare Foundation.
SIGN UP FOR OUR NEWSLETTER
Get the latest thought leadership on multiple myeloma delivered straight to your inbox.
By Bonnie Falbo As the wife of a myeloma patient, and as a new Myeloma Coach for the Myeloma Crowd, I was honored to attend the Inaugural Charlotte Plasma Cell Disorder Congress, hosted by Levine Cancer Institute on August 9-11, 2019. Intended primarily for local health care providers who treat myeloma patients, Myeloma Coaches and […]
Smoldering multiple myeloma was first defined in 1980 by Drs. Kyle and Greipp as “an asymptomatic plasma cell disorder.” The annual risk of progression from smoldering myeloma to symptomatic multiple myeloma is 10% per year for the first 5 years, 5% per year during the following 5 years and only 1% per year after 10 years. […]
A phase II study is open evaluating how well daratumumab, ixazomib, and dexamethasone work with or without bortezomib in treating patients with newly diagnosed multiple myeloma. Please not that for one of the patient groups, it will use two different types of proteasome inhibitors in consecutive order. Open-Label: Patients and their doctors will know both the […]